- Home
- FOXF vs RCKT Comparison
FOXF vs RCKT Comparison
Compare FOXF & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FOXF
- RCKT
- Stock Information
- Founded
- FOXF 2007
- RCKT 1999
- Country
- FOXF United States
- RCKT United States
- Employees
- FOXF N/A
- RCKT N/A
- Industry
- FOXF Motor Vehicles
- RCKT Biotechnology: Pharmaceutical Preparations
- Sector
- FOXF Consumer Discretionary
- RCKT Health Care
- Exchange
- FOXF Nasdaq
- RCKT Nasdaq
- Market Cap
- FOXF N/A
- RCKT 264.0M
- IPO Year
- FOXF N/A
- RCKT N/A
- Fundamental
- Price
- FOXF $28.98
- RCKT $2.99
- Analyst Decision
- FOXF Buy
- RCKT Buy
- Analyst Count
- FOXF 7
- RCKT 13
- Target Price
- FOXF $36.43
- RCKT $18.50
- AVG Volume (30 Days)
- FOXF 502.6K
- RCKT 3.8M
- Earning Date
- FOXF 07-31-2025
- RCKT 08-04-2025
- Dividend Yield
- FOXF N/A
- RCKT N/A
- EPS Growth
- FOXF N/A
- RCKT N/A
- EPS
- FOXF N/A
- RCKT N/A
- Revenue
- FOXF $1,415,479,000.00
- RCKT N/A
- Revenue This Year
- FOXF $5.17
- RCKT N/A
- Revenue Next Year
- FOXF $6.34
- RCKT N/A
- P/E Ratio
- FOXF N/A
- RCKT N/A
- Revenue Growth
- FOXF 1.26
- RCKT N/A
- 52 Week Low
- FOXF $17.95
- RCKT $2.19
- 52 Week High
- FOXF $54.86
- RCKT $26.98
- Technical
- Relative Strength Index (RSI)
- FOXF 68.06
- RCKT 45.55
- Support Level
- FOXF $27.55
- RCKT $2.76
- Resistance Level
- FOXF $29.56
- RCKT $3.24
- Average True Range (ATR)
- FOXF 1.18
- RCKT 0.19
- MACD
- FOXF 0.24
- RCKT 0.17
- Stochastic Oscillator
- FOXF 89.69
- RCKT 74.85
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.